Lynwood Capital Management’s BioPlus Acquisition Corp. Class A Ordinary Shares BIOS Stock Holding History

Lynwood Capital Management’s Portfolio BIOS Stock Details BIOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10,000	Closed	-$104K	–	164
2023 Q1	$104K	Hold	10,000	–	–	0.09%	88
2022 Q4	$103K	Sell	10,000 -15,000	-60%	-$152K	0.12%	84
2022 Q3	$251K	Hold	25,000	–	–	0.27%	84
2022 Q2	$249K	Hold	25,000	–	–	0.28%	79
2022 Q1	$247K	Buy	+25,000	New	+$247K	0.27%	82

Other funds holding BIOS

WCMNY

Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return

Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return

Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return

RCM

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return

WRBC

W.R. Berkley Corp Greenwich, Connecticut $2.18B AUM 13.58% 1-Year Est. Return

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

Quarry LP New York $1.2B AUM 47.63% 1-Year Est. Return

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Lynwood Capital Management's BIOS Position: Q2 2023 in Review

Lynwood Capital Management sold out of BioPlus Acquisition Corp. Class A Ordinary Shares (BIOS) in Q2 2023, closing a stake of 10,000 shares — an estimated $104K sold.

Lynwood Capital Management first reported a position in BIOS in Q1 2022 and held it in 5 quarters. The position peaked at $251K in Q3 2022. 32 funds tracked by Wall St. Rank hold BIOS as of Q2 2023.

Lynwood Capital Management reported no remaining BioPlus Acquisition Corp. Class A Ordinary Shares position as of Q2 2023 after selling out during the quarter.
Lynwood Capital Management sold 10,000 BioPlus Acquisition Corp. Class A Ordinary Shares shares in Q2 2023, an estimated $104K.
Lynwood Capital Management first reported a position in BioPlus Acquisition Corp. Class A Ordinary Shares in Q1 2022 and held it in 5 quarters.
Lynwood Capital Management's BioPlus Acquisition Corp. Class A Ordinary Shares position peaked at $251K in Q3 2022.
32 funds tracked by Wall St. Rank held BioPlus Acquisition Corp. Class A Ordinary Shares as of Q2 2023.

Based on Lynwood Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.